Aflibercept misses endpoint in mid-stage study

Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a mid-stage goal for an ovarian cancer trial. The primary goal was a five percent response for established criteria at two dosages. At the higher dose, researchers tracked a 4.5 percent response and a 0.9 percent response at the lower dose.

Aflibercept is also being tested in late-stage trials for prostate, colorectal, pancreatic and non-small cell lung cancers. Both companies say they're now evaluating how to proceed developing the therapy.

- take a look at the announcement
- read the AP story

Related Articles:
Sanofi snags bigger stake, new pact with Regeneron
Sanofi, Regeneron launch late-stage cancer studies
Regeneron wins rich pact for VEGF trap

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.